• Operational Excellence
  • Reports
  • Lectureships
  • Careers
  • Contact
  • PHRI Staff
    • Outlook.com
    • Webmail
    • PHRI Intranet
    • HHS Hub
    • PHRI LMS
    • McMaster Intranet
    • myHR Login
    • MyPassword
    • HHS COVID-19 self assessment
    • Citrix
  • Site Support
    • DFexplore/ iDataFax
    • RSSM Form
PHRI Menu
  • About
  • Research
  • Team
  • Recent Publications
  • News
  • Collaborations

Bayer Canada and PHRI partner on COVID-19 research

20 May 2020

Share:
  • Homepage
  • >
  • News
  • >
  • Bayer Canada and PHRI partner on COVID-19 research

PHRI and the Canadian arm of Bayer have committed $0.5-million and $1.5-million respectively to initiate a major clinical research program: the Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT) study.

Bayer has pledged to supply study drugs, namely chloroquine, interferon-beta-1b and rivaroxaban, to support the research.

“We believe an approach of combination therapy, targeting different pathways, will likely lead to the greatest benefit,” says Dr. Salim Yusuf, Executive Director of PHRI. “Marked inflammation, a hallmark of severe COVID-19 disease, tends to destroy the lungs and damage the heart, brain and kidneys. There is also superimposed thrombosis, choking blood supply to key organs.”

“Interferon-beta has antiviral effects, and chloroquine blocks the entry of the virus into the cell. Anti-inflammatory drugs such as colchicine reduce the secondary inflammation, and antithrombotics (rivaroxaban and aspirin) prevent clotting in the blood vessels.”

Bayer Canada's Shurjeel Choudhri

Shurjeel Choudhri

Dr. Shurjeel Choudhri, Senior Vice-President and Head of Medical and Scientific Affairs, Bayer Canada, sees the inclusion of outpatients, as well as inpatients, in the ACT COVID-19 study, as important and unique.

“So far, most large studies have been done in hospitals and often on patients who were already on mechanical ventilation,” he says. β€œAt that time, the disease is typically so severe that it can be very difficult to know whether a drug is making a difference.”

PHRI and Bayer Canada have plans for more than 100 contributing research locations and approximately 4,000 patients. They hope to find insights into who is most at risk for severe outcomes from COVID-19, including differences relating to ethnicity and underlying comorbidities.

Editor’s note: Since the writing of this news article, the ACT COVID-19 study protocol has been adjusted, and approved by Health Canada, to remove the drug, chloroquine.

Keep Reading

Research highlights, events, media coverage of PHRI and more.

View All Posts

June 25, 2020

Federal rapid research funding for COVID-19 studies

A total of 17 McMaster University research projects, including two led by PHRI scientists, are among the recipients of the...

Read More

Back To Top

Sign up for the PHRI Pulse Newsletter

PHRI Pulse Newsletter

Don't miss out on the latest health research news from the Population Health Research Institute in Hamilton, Canada

  • This field is for validation purposes and should be left unchanged.
PHRI

PHRI is a joint institute of McMaster University and Hamilton Health Sciences

Research
  • Landmark Studies
  • ACS & Interventional Cardiology
  • Arrhythmia & Heart Failure
  • Biomarkers & Genetics
  • Brain Health & Stroke
  • Cancer Survivorship
  • CVD Prevention
  • Diabetes, Metabolism & Obesity
  • Global & Population Health
  • Infectious Diseases
  • Knowledge Translation & Health Systems
  • Perioperative & Surgery
  • Renal
  • Thrombosis
Team
  • Leadership
  • Senior Scientists
  • Scientists
  • Investigators
  • Fellows
  • Associates
  • Operations
  • Colleagues Remembered
  • International Fellows
Learn More
  • Program Management
  • Statistics
  • Information Technology
  • Financial Services
  • Contracts
  • Quality Assurance
  • Research Specimens
  • CRLB-GMEL
Organization
  • About PHRI
  • Lectureships
  • News
  • Careers
  • Newsletter
  • Reports
  • Contact
  • Media Inquiries
Contact Us

237 Barton Street East
Hamilton, ON L8L 2X2
Canada

Follow @PHRIresearch

© 2023 PHRI. All rights reserved.

  • Data Sharing
  • Privacy Policy
  • Terms and Conditions
  • Newsletter Unsubscribe

Crafted with love by Forge and Smith.